Agenda 2023

The dengue endgame: imagining a world with dengue control

Wednesday, August 9, 2023

Time	Session
8:00am – 8:30am	Arrival, registration, and coffee
8:30am – 8:40am	Welcome and introductions
8:40am – 10:20am	Session #1. Framing the challenge: current state of dengue on the ground Objective: to discuss and review the current and historic challenges associated with dengue control in Asia and the Americas Shirin Kalimuddin, MBBS, MRCP: “Dengue in Singapore: Changing Tides” Darunee Buddharij, MD: “Dengue in Thailand – What have we learned?” Ernesto Marques, MD PhD: “Dengue in Brazil” Laura Adams, DVM, MPH: “Dengue in Puerto Rico – Historical & Current Status” Moderated discussion: Dr. Albert Ko, MD (Yale)
10:20am – 10:40am	Coffee break
10:40am – 12:00pm	Session #2. Framing the challenge: fundamental features of dengue Objective: to discuss and review the fundamental virologic and immunologic features of dengue Alan Rothman, MD: “Immune imprinting in dengue and related flaviviruses” Gregory Gromowski, PhD: “Dengue antibody-dependent enhancement” Anna Durbin, PhD: “Dengue vaccines: what have we learned and what is next” Moderated discussion: Steve Whitehead, PhD (NIAID, NIH)
12:00pm – 1:00pm	Lunch Break
1:00pm – 2:40pm	Session #3. Predicting the unpredictable: models of dengue transmission Objective: to discuss and review advances in dengue modeling Taia Wang, MD PhD: “Antibody correlates of dengue immunity and pathogenesis” Daniela Weiskopf, PhD: “T cell responses as predictors of dengue outcomes” Martin Hibberd, PhD: “Deployment of antivirals as a tool for outbreak control” Alex Perkins, PhD: “Optimal control of dengue with existing interventions” Moderated discussion: Michael Johansson, PhD (CDC)
2:40pm – 3:00pm	Closing remarks, Day 1
3:00pm – 3:30pm	Group Photo (Roof Terrace)
3:30pm – 5:00pm	Happy hour and poster session (Grand Hall)

Thursday, August 10, 2023

Time	Session
8:30am – 8:50am	Arrival and coffee
8:50am – 9:00am	Welcome and recap of Day 1
9:00am – 10:40am	Session #4. Looking to the future: new tools and approaches for dengue control Session Objective: to discuss and review selected early-stage dengue countermeasures and interventions Ashley St. John, PhD: “Host-directed therapeutics for dengue” Adam Waickman, PhD: “Beyond mucosal immunity: defining a role for IgA in dengue pathogenesis and immunity” Rebecca Christofferson, PhD: “What can we learn from Covid-19 about vector control efficacy communication?” Stephen Thomas, MD: “Human challenge models as tools for accelerating dengue countermeasure deployment” Moderated discussion: Sophie Yacoub, MD PhD
10:40am – 11:00am	Coffee break
11:00am – 12:00pm	Session #5. Advanced-stage countermeasures: vaccines Objective: to discuss the current status of advanced-stage countermeasure clinical development Angel Rosas, PhD: “TAK-003 (Tetravalent Dengue Vaccine Candidate)” Louis Macareo, MD, JD, MPH: “V181 dengue vaccine program” Moderated discussion: Eng Eong Ooi, MD PhD
12:00pm – 1:30pm	Lunch Break
1:30pm – 2:30pm	Session #6. Advanced-stage countermeasures: therapeutics Objective: to discuss the current status of advanced-stage countermeasure clinical development Bhagwat Gurnale, MD: “Dengue monoclonal antibody: Clinical development update” Tine De Marez, PhD and Anna Durbin, PhD: “Antiviral activity, safety, and pharmacokinetics of JNJ-1802” Moderated discussion: Nelson Michael, MD PhD
2:30pm – 3:00pm	Break
3:00pm – 4:30pm	Session #7. Putting the pieces together Objective: discussing reviewing ongoing integrated dengue control efforts Sophie Yacoub, MD PhD: “Innovations and therapeutics to facilitate dengue control: the beginning of the end” Gabriela Paz-Bailey, MD PhD: “Working towards dengue elimination in Puerto Rico” Eng Eong Ooi, MD PhD: “Ending dengue in Singapore? Down the rabbit-hole.” Moderated discussion: Stephen Thomas, MD
4:30pm – 5:00pm	Closing remarks, day 2